About us
Our name
The name Curadh (pronounced Cure-rad) is derived from a Scottish Gaelic word meaning ‘warrior’.
We, the Curadh team, have been fighting cancer all our professional careers and remain as committed as ever to that fight. But there is also an added significance to the letters ‘Cur’, which form part of the word ‘cure’, and the letters ‘rad’ which form part of the word ‘radiation’, referencing the new field of Molecularly Targeted Radiation. The silent ‘H’ represents ‘hope’, a key driver for all of us at Curadh, and giving silent hope for a cure to patients and their families.
Curadh is dedicated to improving and accelerating the development of molecularly targeted radiation therapies for patients who are waiting
Alison Armour
Founder & Chief Medical Officer
Alison was an experienced medical and radiation oncologist, with a doctorate in MTR, before joining industry 20 years ago. She is skilled in all stages of drug and diagnostic development. As Chief Medical Officer of Endocyte, Alison clinically developed PSMA617, designing the Phase III VISION registration trial and leading all global regulatory interactions and clinical operations. She supported investigator studies of PSMA617 in combination with DNA repair inhibitors, immune oncology and hormonal therapies as well as obtaining first regulatory approval of PSMA617 based on Phase II data prior to transition to Novartis in December 2018. The drug was approved in 2022 and is now known as Pluvicto.
Glenn Kazo
Chief Executive Officer
Glenn has over 30 years of experience in the biopharma sector as a C-Suite executive, corporate officer and scientist, with extensive corporate financing, venture investing, strategic planning, business development and marketing experience in the global health arena. Glenn has been responsible for raising over $500 million from international investors, including leading efforts in three successful IPOs. Mr. Kazo is widely recognized as a co-founder of Enzon, Inc., the pioneering drug delivery company that created Pegylation technology, a platform which continues to expand with numerous products on the market that have collectively generated over $180 billion in sales. He currently serves as founder and Board member for several early stage biopharma and medical device companies and as an advisor to healthcare investors.
Amrik Basran
Chief Scientific Officer
Amrik has over 20 years of experience in biotech and pharma, developing biotherapeutic platforms from the bench to the clinic at companies such as Domantis, GSK and Avacta Therapeutics. At GSK he was the Head of Topical Delivery (Biopharm Discovery Unit), supporting the development/formulation of antibodies and domain antibodies for delivery into the eye, skin and lung to treat inflammatory diseases. As the Chief Scientific Officer at Avacta Therapeutics, he and his team developed the human Affimer platform for novel therapeutic applications in oncology with partners such as Moderna, LG Chem and Daewoong. More recently Amrik has worked as Chief Discovery Officer at Turbine.AI, validating biological hypothesis generated by their machine learning Simulated CellTM platform using their internal small molecule oncology pipeline.
Colin Wheeler
Chief Regulatory Officer
Colin is a UK registered physician (MBChB) with a Diploma in Pharmaceutical Medicine (DipPharmMed), over 25 years’ experience of Haem / Oncology drug development and regulatory roles in both the US and EU, and with personal experience of over 200 FDA and EMA regulatory interactions.
Bob Seevers
VP Regulatory/ CMC
Bob has 40 years’ experience as a former FDA reviewer and regulatory/quality lead for Lilly and expertise in working with FDA, submissions, large and small molecules, cold chain, quality, training, and due diligence.
Chris Clark
Chief Financial Officer
Chris has over 20 years of experience as a finance leader in life sciences, with extensive cross border M&A, turnaround, IPO and operational experience, specifically within contract research organizations and biotech. He has a track record of building expert teams and companies both in the US and the UK. He is currently a Board Trustee and Audit Chairman with Worldwide Cancer Research.
Aily Armour
Chief Commercial Officer
Aily has 35 years of international investment and commercial banking experience, with a proven track record in deal origination specifically within the nuclear energy, finance, commodity trading.